We are live on ! Find out more
DFTX

Definium Therapeutics
DFTX

181 hedge funds and large institutions have $271M invested in Definium Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 57 increasing their positions, 49 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more call options, than puts

Call options by funds: $6.9M | Put options by funds: $4.38M

16% more repeat investments, than reductions

Existing positions increased: 57 | Existing positions reduced: 49

13% more capital invested

Capital invested by funds: $241M → $271M (+$30.5M)

0.71% more ownership

Funds ownership: 54.61% → 55.32% (+0.71%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

5% less funds holding

Funds holding: 190 → 181 (-9)

33% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 27

Holders
181
Holders Change
-9
Holders Change %
-4.74%
% of All Funds
2.38%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
18
Increased
57
Reduced
49
Closed
27
Calls
$6.9M
Puts
$4.38M
Net Calls
+$2.52M
Net Calls Change
-$1.47M

Top Buyers

1
Marshall Wace
Marshall Wace
United Kingdom
+$5.45M
2
CC
Commodore Capital
New York
+$3.12M
3
UBS Group
UBS Group
Switzerland
+$2.67M
4
ABG
Ally Bridge Group
New York
+$2.21M
5
TCM
Tang Capital Management
California
+$1.32M

Top Sellers

1
OCA
Octagon Capital Advisors
New York
-$5.84M
2
WP
Woodline Partners
California
-$3.31M
3
DCM
Driehaus Capital Management
Illinois
-$1.7M
4
Citadel Advisors
Citadel Advisors
Florida
-$1.54M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.16M
Name Holding Trade Value Shares
Change 		Change in
Stake
Daiwa Securities Group
151
Daiwa Securities Group
Japan
$2K – – –
RIL
152
Rothschild Investment LLC
Illinois
$1.77K +$1.78K +270 +9,000%
PA
153
Parallel Advisors
California
$1.63K +$1.53K +233 +1,226%
AEPWM
154
Atlantic Edge Private Wealth Management
Florida
$1.25K – – –
NA
155
NewEdge Advisors
Louisiana
$921 – – –
PW
156
Pandora Wealth
Illinois
$850 – – –
FPF
157
First Pacific Financial
Washington
$662 +$671 +102 New
HWM
158
HighMark Wealth Management
Minnesota
$649 – – –
EWA
159
EverSource Wealth Advisors
Alabama
$584 +$224 +34 +61%
AF
160
Allworth Financial
California
$552 +$105 +16 +23%
AWM
161
Activest Wealth Management
Florida
$428 – – –
Fifth Third Bancorp
162
Fifth Third Bancorp
Ohio
$383 – – –
PS
163
Principal Securities
Iowa
$376 +$381 +58 New
TCM
164
Tradewinds Capital Management
Washington
$344 – – –
LI
165
Louisbourg Investments
New Brunswick, Canada
$337 – – –
ACM
166
Anfield Capital Management
California
$234 – – –
PMFA
167
Plante Moran Financial Advisors
Michigan
$234 – – –
CAM
168
Chesapeake Asset Management
New York
$214 – – –
TCM
169
TruNorth Capital Management
Michigan
$214 – – –
RF
170
Robbins Farley
New Hampshire
$182 – – –
TIM
171
Total Investment Management
Arizona
$130 +$132 +20 New
PNC Financial Services Group
172
PNC Financial Services Group
Pennsylvania
$110 +$112 +17 New
CB
173
CNB Bank
Pennsylvania
$65 – – –
MCM
174
MAI Capital Management
Ohio
$65 – – –
BC
175
Belmont Capital
California
$39 – – –
5 6
7
8 9

DFTX Hedge Fund Activity: Q2 2025 in Review

181 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2025, worth a combined $271M — up 13% from $241M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of DFTX and 18 opened new positions — a net loss of 9 holders — while 49 trimmed existing stakes and 57 added.

The largest buyer was Marshall Wace, adding an estimated $5.45M. The largest seller was Octagon Capital Advisors, cutting an estimated $5.84M.

  • 181 institutional investors held Definium Therapeutics (DFTX) as of Q2 2025, down from 190 in Q1 2025.
  • Funds reported $271M of Definium Therapeutics stock for Q2 2025, up 13% quarter-over-quarter.
  • 18 funds opened new Definium Therapeutics positions in Q2 2025 and 27 closed out, a net change of -9 holders.
  • The largest Definium Therapeutics buyer in Q2 2025 was Marshall Wace, an estimated $5.45M added.
  • The largest Definium Therapeutics seller in Q2 2025 was Octagon Capital Advisors, an estimated $5.84M sold.

Based on aggregated 13F filings for Q2 2025.